1173884-72-4

Upstream product

• 1173884-71-3 C₃₉H₄₂N₂O₄ 
• 1173884-70-2 C₃₉H₄₀O₅ 
• 18325-99-0 (3aR,6aS,7R,10R,10aR,10bS)-3a,10a-dihydroxy-5-(hydroxymethyl)-2,10-dimethyl-7-(prop-1-en-2-yl)-3a,4,6a,7,10,10a-hexahydrobenzo[e]azulene-3,8(9H,10bH)-dione 
• 17673-25-5 phorbol 

Downstream Products

• 1173884-88-2 C₄₁H₄₆N₂O₅ 
• 1173884-75-7 C₄₇H₄₈N₂O₆ 
• 1173884-90-6 C₃₉H₄₁BrN₂O₄ 
• 1338721-14-4 C₅₁H₅₀O₆ 
• 1338713-40-8 C₅₁H₅₀O₆ 
• 1449214-06-5 C₅₁H₅₄O₆ 
• 1262389-80-9 C₅₃H₅₂O₆ 
• 1338721-49-5 C₅₁H₅₈O₆ 
• 1449214-07-6 C₅₄H₅₄O₆ 
• 1262389-99-0 C₂₈H₄₀O₆ 
• 1262389-96-7 C₂₈H₂₉F₅O₆ 
• 1262389-81-0 C₃₄H₃₈O₆ 
• 1173884-74-6 C₂₀-O-trityl-prostratin 
• 1262389-74-1 C₂₀-O-trityl-prostratin-ol 

Relevant academic research and scientific papers

Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo

Highly active antiretroviral therapy (HAART) decreases plasma viremia belowthe limits of detection in the majority of HIV-infected individuals, thus serving to slow disease progression. However, HAART targets only actively replicating virus and is unable

Process to Produce Prostratin and Structural or Functional Analogs Thereof

This invention concerns a process to convert a hydroxyl group (bold in R3C—OH) in a tigliane-type compound to a hydrogen (bold in R3C—H) to obtain deoxytigliane-type compounds or structural or functional analogs thereof. The process has wide application particularly to produce specific biologically active compounds in quantity for use as pharmaceuticals. In particular the process can be used to convert phorbol to a 12-deoxytigliane (prostrating which is a therapeutic lead for the treatment of AIDS. New compositions of matter are also disclosed.